Search Results - "Amour, E."

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial by Heerspink, Hiddo J L, Sjöström, C David, Jongs, Niels, Chertow, Glenn M, Kosiborod, Mikhail, Hou, Fan Fan, McMurray, John J V, Rossing, Peter, Correa-Rotter, Ricardo, Kurlyandskaya, Raisa, Stefansson, Bergur V, Toto, Robert D, Langkilde, Anna Maria, Wheeler, David C

“…Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the…”
Get full text

Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA) by Wislez, M., Blons, H., Domblides, C., Barlesi, F., Mazieres, J., Monnet, I., Kiakouama Maleka, L., Quantin, X., Taillade, L., Lena, H., Fraisse, P., Janicot, H., Audigier Valette, C., Amour, E., Langlais, A., Rabbe, N., Cadranel, J., Laurent puig, P., Lavolé, A.

Get full text

IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer by Mignard, X, Antoine, M, Moro-Sibilot, D, Dayen, C, Mennecier, B, Gervais, R, Amour, E, Milleron, B, Morin, F, Zalcman, G, Wislez, M

“…Programmed cell death-ligand 1 (PD-L1) is a checkpoint receptor that facilitates immune evasion by tumor cells, through interaction with programmed cell…”
Get more information

The relative importance of large mammal species for tourism in Amboseli National Park, Kenya by Okello, Moses Makonjio, Manka, Stephanie Grace, D’Amour, Danielle E.

“…Marketing for tourism in Kenya mostly revolves around “the big five” charismatic large mammals. However, it is not known if these are in fact the species…”
Get full text

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial by Peters, S., Dafni, U., Dómine, M., Popat, S., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., López Vivanco, G., Madelaine, J., Faehling, M., Griesinger, F., González Larriba, J.L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Le Pechoux, C., De Ruysscher, D., Stahel, R., Hiltbrunner, A., Gasca-Ruchti, A., Giacomelli, N., Kammler, R., Marti, N., Pfister, R., Piguet, A.C., Roux, S., Troesch, S., Schweri, R., Zigomo, I., Tsourti, Z., Tsouprou, S., Kassapian, M., Vervita, K., Dimopoulou, G., Andriakopoulou, C., Morin, F., Amour, E., Mariaule, G., Archirel, N., Fernandez, M., Pereira, E., Benito, L., Lopez, K., Hernández, A., Chinchen, S., Jurkovic, H., Livingstone, A., Walker, M., Mitchell, P., Ng, S., Steer, C., Briscoe, K., Saqib, A., O’Byrne, K., Chittajallu, B.R., Hughes, B.G., Black, A., Nackaerts, K., Werner, H., Gervais, R., Zalcman, G., Monnet, I., Moro-Sibilot, D., Molinier, O., Girard, N., Souquet, P.-J., Barlesi, F., Debieuvre, D., Senellart, H., Poudenx, M., Dixmier, A., Pouessel, D., Cadranel, J., Lena, H., Quoix, E., Friard, S., Audigier-Valette, C., Mazieres, J., Pichon, E., Faehling, M., Kokowski, K., Griesinger, F., Tufman, A., de Langen, J., González Larriba, J.L., Insa, A., Massutí, B., Pulla, M.P., Aix, S.P., Villanueva, N., Andrade, J., Curioni-Fontecedro, A., Franks, K., Califano, R.

“…Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI) is the standard treatment in limited-disease small-cell…”
Get full text

1291O Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial by Vera, P., Le Tinier, F., Chaumet-Riffaud, P., Martin, E., Pourel, N., Boisselier, P., Salem, N., Le Pechoux, C., Giroux-Leprieur, E., Guillerm, S., Valette, C. Audigier, Lerouge, D., Massabeau, C., Moisson, P., Larrouy, A., Hapdey, S., Langlais, A., Amour, E., Zalcman, G., Giraud, P., Thureau, S.

Get full text

Lymphangiomas in children: MR imaging by Siegel, M J, Glazer, H S, St Amour, T E, Rosenthal, D D

“…Seventeen lymphangiomas in 15 patients were imaged with magnetic resonance (MR) to define the nature, extent, and anatomic relationships of these lesions. The…”
Get more information

3:54 PMAbstract No. 272 - Percutaneous irreversible electroporation of colorectal cancer metastasis to the liver: a single institution experience by Amour, E. St, Weintraub, J., Yang, P., Antoine, S., Hays, D.

Get full text

1405PCirculating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA) by Wislez, M, Blons, H, Domblides, C, Barlesi, F, Mazieres, J, Monnet, I, Kiakouama Maleka, L, Quantin, X, Taillade, L, Lena, H, Fraisse, P, Janicot, H, Audigier Valette, C, Amour, E, Langlais1, A, Rabbe, N, Cadranel, J, Laurent puig, P, Lavolé, A

Get full text

Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) by Zalcman, G., Mazieres, J., Greillier, L., Brosseau, S., Lantuejoul, S., Do, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Guisier, F., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

Get full text

1591TiP - IFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment by Zalcman, G., Toffart, A.C., Madroszyk Flandin, A.-C., Molinier, O., Dayen, C., Egenod, T., Dixmier, A., Giroux Leprieur, E., Masson, P., Cloarec, N., Thibonnier, L., Favier, L., Debieuvre, D., Mazieres, J., Van Hulst, S., Pichon, E., Amour, E., Morin, F., Souquet, P.-J.

“…We raise the hypothesis that a STOP and GO strategy with induction by double immunotherapy Nivolumab + Ipilimumab combination during 6 months, followed by…”
Get full text

1841OSecond/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) by Zalcman, G, Mazieres, J, Greillier, L, Brosseau, S, Lantuejoul, S, Do, P, Bylicki, O, Monnet, I, Corre, R, Audigier-Valette, C, Locatelli-Sanchez, M, Molinier, O, Guisier, F, Urban, T, Planchard, D, Ligeza-Poisson, C, Amour, E, Morin, F, Moro-Sibilot, D, Scherpereel, A

“…Abstract Background The phase IIR trial IFCT-1501 (MAPS2) tested nivo or nivo+ipi in pts with relapsed MPM as second/third-line. This trial reached its primary…”
Get full text

1841O - Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD) by Zalcman, G., Mazieres, J., Greillier, L., Brosseau, S., Lantuejoul, S., Do, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Guisier, F., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

“…The phase IIR trial IFCT-1501 (MAPS2) tested nivo or nivo+ipi in pts with relapsed MPM as second/third-line. This trial reached its primary endpoint with 40%…”
Get full text

IFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment by Zalcman, G., Toffart, A.C., Madroszyk Flandin, A.-C., Molinier, O., Dayen, C., Egenod, T., Dixmier, A., Giroux Leprieur, E., Masson, P., Cloarec, N., Thibonnier, L., Favier, L., Debieuvre, D., Mazieres, J., Van Hulst, S., Pichon, E., Amour, E., Morin, F., Souquet, P.-J.

Get full text

1591TiPIFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment by Zalcman, G, Toffart, A C, Madroszyk Flandin, A-C, Molinier, O, Dayen, C, Egenod, T, Dixmier, A, Giroux Leprieur, E, Masson, P, Cloarec, N, Thibonnier, L, Favier, L, Debieuvre, D, Mazieres, J, Van Hulst, S, Pichon, E, Amour, E, Morin, F, Souquet, P-J

“…Abstract Background We raise the hypothesis that a STOP and GO strategy with induction by double immunotherapy Nivolumab + Ipilimumab combination during 6…”
Get full text

Evidence of leopard predation on bonobos (Pan paniscus) by D'Amour, Danielle E, Hohmann, Gottfried, Fruth, Barbara

“…Current models of social organization assume that predation is one of the major forces that promotes group living in diurnal primates. As large body size…”
Get more information

Agricultural expansion within Kimana electric fences and implications for natural resource conservation around Amboseli National Park, Kenya by Okello, M.M., D’Amour, D.E.

“…Fencing has become a key strategy in mitigating human–wildlife conflicts and promoting agricultural production in Kenya. However, it can have negative…”
Get full text

Percutaneous irreversible electroporation of colorectal cancer metastasis to the liver: a single institution experience by Amour, E. St, Weintraub, J, Yang, P, Antoine, S, Hays, D

Get full text

Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial by Zalcman, G., Mazieres, J., Greillier, L., Lantuejoul, S., Dô, P., Bylicki, O., Monnet, I., Corre, R., Audigier-Valette, C., Locatelli-Sanchez, M., Molinier, O., Thiberville, L., Urban, T., Planchard, D., Ligeza-Poisson, C., Amour, E., Morin, F., Moro-Sibilot, D., Scherpereel, A.

Get full text

Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial by Girard, Nicolas, Mornex, Françoise, Douillard, Jean-Yves, Bossard, Nadine, Quoix, Elisabeth, Beckendorf, Véronique, Grunenwald, Dominique, Amour, Elodie, Milleron, Bernard

“…Abstract Locally advanced non-small cell lung cancers share a risk of both local and systemic recurrence and justifies a therapeutic strategy combining focal…”
Get full text